Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics

Bowman L.; Chen F.; Sammons E.; Hopewell J. C.; Wallendszus K.; Stevens W.; Valdes-Marquez E.; Wiviott S.; Cannon C. P.; Braunwald E.; Il Collins; Landray M. J.

首页> 外文期刊>The American heart journal >Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics

【24h】

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics

机译：随机评估厌氧物通过脂质改性（揭示）-A大规模，随机，安慰剂对照试验，血管疾病患者胸腺嘧啶的临床影响：试验设计，招聘和基线特征

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipoprotein (HDL) cholesterol. However, it is not known if these apparently favorable lipid changes translate into reductions in cardiovascular events.

机译：尽管存在基于汀类药物的疗程，但背景患者仍处于心血管事件的高风险。通过Anacetrapib抑制胆固醇酯转移蛋白将低密度脂蛋白（LDL）胆固醇降低约25％至40％，并且高于双倍率高密度脂蛋白（HDL）胆固醇。然而，如果这些明显有利的脂质变化转化为心血管事件的减少，则尚不清楚。

著录项

来源
《The American heart journal》 |2017年第2017期|共9页
作者
Bowman L.; Chen F.; Sammons E.; Hopewell J. C.; Wallendszus K.; Stevens W.; Valdes-Marquez E.; Wiviott S.; Cannon C. P.; Braunwald E.; Il Collins; Landray M. J.;
展开▼
作者单位

Univ Oxford REVEAL Cent Coordinating Off Clin Trial Serv Unit Nuffield Dept Populat Hlth;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics [J] . Bowman L., Chen F., Sammons E., The American heart journal . 2017,第期

机译：随机评估厌氧物通过脂质改性（揭示）-A大规模，随机，安慰剂对照试验，血管疾病患者胸腺嘧啶的临床影响：试验设计，招聘和基线特征
2. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure [J] . FoxK., FordI., StegP.G., The American heart journal . 2013,第4期

机译：研究的基本原理，设计和基线特征评估了冠状动脉疾病患者中If抑制剂ivabradine的发病率-死亡率（SIGNIFY试验）：稳定冠心病患者使用ivabradine的随机，双盲，安慰剂对照试验没有临床心力衰竭的动脉疾病
3. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure [J] . FoxK., FordI., StegP.G., The American heart journal . 2013,第4期

机译：研究评估冠状动脉疾病患者抑制剂IVABRADINE的发病率，设计和基线特征，评估冠状动脉疾病患者的发病率 - 死亡率（意思是试验）：稳定冠状动脉患者Ivabradine的随机，双盲，安慰剂对照试验没有临床心力衰竭的动脉疾病
4. Effects of 650 nm-10.6 μm Combined Laser Acupuncture-Moxibustion on Knee Osteoarthritis:A Randomized,Double-blinded and Placebo-controlled Clinical Trial [C] . SHEN Xue-yong, DING Guang-hong, WU Fan, The 3rd Workshop on Scientific Approaches to Chinese Medicine(第三届中医科学研究方法研讨会)论文集 . 2008

机译：650 nm-10.6μm联合激光针灸对膝骨关节炎的影响：一项随机，双盲和安慰剂对照的临床试验
5. A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Effect of Infliximab on General Cognition in a Population of Depressed Individuals with Bipolar Disorder Type I/II [D] . Pan, Zihang. 2018

机译：一项随机，双盲，安慰剂对照的临床试验，评估英夫利昔单抗对I / II型双相情感障碍抑郁症患者总体认知的影响
6. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design recruitment and baseline characteristics [O] . M.J. Landray, REVEAL Collaborative Group -1

机译：通过脂质修饰（REVEAL）评估Anacetrapib的疗效的随机评估-在已确定的血管疾病患者中进行anacetrapib的临床疗效的大规模随机安慰剂对照试验：试验设计募集和基线特征
7. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics [O] . Landray, M, REVEAL Collaborative Group 2017

机译：通过脂质修饰（REVEAL）评估Anacetrapib的疗效的随机评估-在已确定的血管疾病患者中进行anacetrapib的临床疗效的大规模，随机，安慰剂对照试验：试验设计，募集和基线特征

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics

摘要

著录项

相似文献

相关主题

期刊订阅